Axogen, Inc. — fact timeline

Axogen, Inc. reported first quarter ended March 31, 2026 results: revenue $61.5 million, net income Net loss for the first quarter of 2026 was $19.6 million, or $0.38 per share, EPS $0.38 per share. Guidance raised.

“Axogen, Inc. (NASDAQ: AXGN), a global leader in developing and marketing innovative surgical solutions for the restoration of peripheral nerve function, today reported financial results and business highlights for the first quarter ended March 31, 2026. First Quarter Financial Results • First quarter 2026 revenue was $61.5 million”

Axogen, Inc. entered into Underwriting Agreement with Wells Fargo Securities, LLC and Mizuho Securities USA LLC, as representatives of the underwriters valued at 4,000,000 shares of its common stock, $0.01 par value per share, at a public offering price of $31.0 (effective 2026-01-21).

“On January 21, 2026, Axogen, Inc. (the “Company”) entered into an underwriting agreement (the “Underwriting Agreement”) with Wells Fargo Securities, LLC and Mizuho Securities USA LLC, as representatives of the underwriters (the “Underwriters”).”

Lindsey Hartley was appointed as Chief Financial Officer at Axogen, Inc..

“On May 8, 2025, Axogen, Inc. (the “Company”) announced the appointment of Lindsey Hartley as its Chief Financial Officer, effective May 12, 2025”

Nir Naor departed as Chief Financial Officer at Axogen, Inc..

“Nir Naor, the Chief Financial Officer (the “CFO”) of the Company, will step down from his role effective May 11, 2025”

Michael Dale was appointed as Chief Executive Officer, President, and Director at Axogen, Inc..

“On August 8, 2024, Axogen, Inc. (the “Company”), announced the appointment of Michael Dale as its Chief Executive Officer (“CEO”) and President, effective August 9, 2024 (the “Effective Date”).”

Gregory Freitag departed as Director at Axogen, Inc..

“Mr. Gregory Freitag was not re-nominated for re-election.”

Axogen, Inc. reported full year 2024 results: revenue 177 million to 181 million. Guidance reaffirmed.

“We are maintaining our annual revenue guidance in the range of $177 million to $181 million, which represents a growth rate of approximately 11% to 14%.”

Axogen, Inc. reported first quarter ended March 31, 2024 results: revenue 41.4 million, net income -6.6 million, EPS -0.15. Guidance reaffirmed.

“First quarter revenue was $41.4 million, a 12.9% increase compared to the first quarter of 2023.”

Angelo Scopelianos resigned as Chief Research and Development Officer at Axogen, Inc..

“Angelo Scopelianos notified Axogen, Inc. (the “Company”) of his intention to resign as the Company’s Chief Research and Development Officer no later than March 31, 2024 (the “Separation Date”).”

Axogen, Inc. updated its the fourth quarter and full-year ended December 31, 2023 guidance (raised).

“On March 5, 2024 Axogen, Inc. (the “Company”) issued a press release announcing its fourth quarter and full year 2023 financial results.”

Peter Mariani departed as Chief Financial Officer at Axogen, Inc..

“Mr. Mariani’s severance benefits in connection with his departure include a severance amount equal to 12 months of his current base compensation and COBRA benefits for 12 months after he ceased to be an employee of the Company on December 22, 2023 (the “Separation Date”).”

Axogen, Inc. reported full year 2023 results: revenue $158.8 million. Guidance reaffirmed.

“Full-year 2023 revenue is expected to be approximately $158.8 million, which represents a 15% increase over the full-year of 2022.”

Axogen, Inc. reported fourth quarter 2023 results: revenue $42.7 million.

“Fourth quarter revenue is expected to be approximately $42.7 million, which represents an 18% increase over the fourth-quarter of 2022 driven by solid performance across the product portfolio.”

Karen Zaderej departed as Chief Executive Officer and President at Axogen, Inc..

“Retirement of Karen Zaderej Karen Zaderej, the Chief Executive Officer (the “CEO”) and President of the Company informed the Company of her intention to retire in January 2025.”

Kathy Weiler was appointed as Director at Axogen, Inc..

“On December 20, 2023, the board of directors (the “Board”) of Axogen, Inc. (the “Company”) increased the size of the Board from nine directors to ten directors, and appointed Kathy Weiler to fill the newly created vacancy effective December 20, 2023.”

Peter Mariani departed as Executive Vice President and Chief Financial Officer at Axogen, Inc..

“Effective upon Mr. Naor’s appointment, Peter Mariani stepped down from his role as the Executive Vice President and Chief Financial Officer of the Company and Axogen Corporation, a Delaware corporation (“AC”) and wholly owned subsidiary of the Company, at the request of the Board.”

Nir Naor was appointed as Chief Financial Officer at Axogen, Inc..

“On December 6, 2023, Axogen, Inc. (the “Company”) announced the appointment of Nir Naor as Chief Financial Officer, effective December 4, 2023.”

Axogen, Inc. reported full year 2023 results: revenue $154 million to $159 million. Guidance reaffirmed.

“Management is maintaining full-year 2023 revenue guidance in the range of $154 million to $159 million, which represents annual growth of 11% - 15%.”

Axogen, Inc. reported third quarter ended September 30, 2023 results: net income Net loss of $4.1 million, EPS $0.10 per share.

“Revenue was $41.3 million during the third quarter, an increase of approximately 12% over the third quarter of 2022.”

Mike Donovan departed as Vice President of Operations at Axogen, Inc..

“On September 19, 2023, Mike Donovan, the Vice President of Operations of Axogen, Inc. (the “Company”) informed the Company of his intention to retire, effective March 22, 2024 (the “Retirement Date”).”

Axogen, Inc. shareholders approved Amendment to Bylaws to set Board size range of 7 to 11 members and allow Board to set specific number within that range at the 2023-08-15 meeting.

“For Against Abstentions Broker Non-Votes 34,131,162 865,249 81,696 —”

Axogen, Inc. shareholders approved Amendment and restatement of Axogen, Inc. 2017 Employee Stock Purchase Plan to increase shares from 600,000 to 1,200,000 at the 2023-08-15 meeting.

“For Against Abstentions Broker Non-Votes 27,438,032 2,597,564 98,838 4,943,673”

Axogen, Inc. shareholders rejected Amendment and restatement of Axogen, Inc. 2019 Long-Term Incentive Plan to increase shares from 8,000,000 to 10,500,000 at the 2023-08-15 meeting.

“For Against Abstentions Broker Non-Votes 11,294,448 18,612,185 227,801 4,943,673”

Axogen, Inc. shareholders approved Advisory (non-binding) vote on executive compensation of named executive officers at the 2023-08-15 meeting.

“For Against Abstentions Broker Non-Votes 28,598,027 1,372,361 164,046 4,943,673”

Axogen, Inc. shareholders approved Ratification of Appointment of Deloitte & Touche LLP as independent auditor for fiscal year ending December 31, 2023 at the 2023-08-15 meeting.

“For Against Abstentions Broker Non-Votes 34,923,002 146,443 8,662 —”

Axogen, Inc. shareholders approved Election of nine directors to serve for a one-year term until the 2024 annual meeting of shareholders at the 2023-08-15 meeting.

“Nine directors were elected to the Company’s Board of Directors (the "Board") to serve for a one-year term until the 2023 annual meeting of shareholders. The results of the election were as follows: Name For Withheld Broker Non-Votes Karen Zaderej 29,010,146 1,124,288 4,943,673 Amy Wendell 29,004,864 1,129,570 4,943,673 William Burke 28,413,152 1,721,282 4,943,673 Gregory Freitag 29,040,709 1,093,725 4,943,673 John H. Johnson 23,637,550 6,496,884 4,943,673 Alan Levine 29,215,878 918,556 4,943,673 Guido Neels 22,945,316 7,189,118 4,943,673 Paul Thomas 28,834,881 1,299,553 4,943,673 Joseph Tyndall, MD MPH, FACEP 29,410,761 723,673 4,943,673”

Axogen, Inc. updated its six months ended June 30, 2023 guidance (reaffirmed).

“On July 26, 2023, Axogen, Inc. (the “Company”) issued a press release announcing its three and six months ended June 30, 2023 financial results.”

Axogen, Inc. reported second quarter ended June 30, 2023 results: revenue $38.2 million, net income $6.7 million, EPS $0.16 per share. Guidance reaffirmed.

“today reported financial results and business highlights for the second quarter ended June 30, 2023. Second Quarter Financial Results and Business Highlights • Revenue was $38.2 million during the second quarter, an increase of approximately 11% over the second quarter of 2022. • The Company estimates that revenues from scheduled non-trauma procedures”

Axogen, Inc. reported first quarter ended March 31, 2023 results: revenue $36.7 million, net income $7.1 million, EPS $0.17 per share. Guidance reaffirmed.

“today reported financial results and business highlights for the first quarter ended March 31, 2023. First Quarter Financial Results and Business Highlights • Net revenue was $36.7 million, an increase of 18% over the first quarter of 2022. • Gross margin was 81.7%, compared to 82.1% in the first quarter of 2022. • Net loss of $7.1 million, or $0.17 per share,”

Axogen, Inc. reported full year 2023 results: revenue $154 million to $159 million. Guidance initiated.

“Management expects full-year 2023 revenue to be in the range of $154 million to $159 million”

Axogen, Inc. reported full year ended December 31, 2022 results: revenue $138.6 million.

“ved hospital operating environment and commercial execution, backed by our high-quality portfolio of clinical data provides a solid foundation for long term, sustainable growth.” Full-Year Financial Results and Business Highlights • Full-year 2022 revenue was $138.6 million, a 12% increase compared to 2021 revenue of $127.4 million.* • Gross margin was 82.6% for the full year, compared to 82.0% in 2021.”

Axogen, Inc. reported fourth quarter ended December 31, 2022 results: revenue $36.2 million, net income $5.4 million, EPS $0.13 per share.

“Fourth Quarter 2022 Financial Results and Business Highlights • Fourth quarter revenue was $36.2 million, a 17% increase compared to fourth quarter of 2021.* • Gross margin was 83.0% for the fourth quarter compared to 82.8% in the fourth quarter of 2021.”

Axogen, Inc. reported fourth quarter and full-year 2022 results: revenue approximately $36.1 million, a 16% increase compared to fourth-quarter 2021 excluding the impact of Avive revenue in 202.

“Axogen Reports Preliminary Unaudited Revenue for Fourth Quarter and Full-Year 2022”

Axogen, Inc. reported third quarter ended September 30, 2022 results: revenue $37.0 million, net income $(4.3) million, or $(0.10) per share. Guidance reaffirmed.

“reported financial results and business highlights for the third quarter ended September 30, 2022. Third Quarter Financial Results 2022 and Business Highlights • Net revenue was $37.0 million during the third quarter, an increase of 18% over the third quarter of 2021.* • Gross margin was 83.3% for the quarter compared to 83.2% in the third quarter of 2021. • Net loss”

Joseph Adrian Tyndall was appointed as Director at Axogen, Inc..

“On October 25 2022, the Company's Board appointed Joseph Adrian Tyndall, M. D. as a new director to fill the vacant directorship on the Board, effective December 13, 2022.”

Mark Gold resigned as Director at Axogen, Inc..

“On October 24, 2022, Mark Gold, M.D. notified Axogen, Inc. (the “Company”) of his decision to resign as a member of the Company’s Board of Directors (the “Board”), including as a member of the Quality, Compliance and Portfolio Management Committee, effective as of 3:00 PM EST on Tuesday, December 13, 2022.”

Eric Sandberg was terminated as Chief Commercial Officer at Axogen, Inc..

“On July 12, 2022, Axogen Corporation, a Delaware corporation (“AC”) and wholly owned subsidiary of the Company, and Eric Sandberg, the Company’s Chief Commercial Officer, agreed that his employment would be terminated without Substantial Cause (as defined in the Employment Agreement (as defined below)), effective as of July 19, 2022.”

William Burke was appointed as Director at Axogen, Inc..

“On July 8, 2022, the board of directors (the “Board”) of Axogen, Inc. (the “Company”) appointed William Burke as a new director to fill the vacant directorship on the Board, effective July 11, 2022.”

Quentin S. Blackford resigned as Director at Axogen, Inc..

“On March 29, 2022, Quentin S. Blackford notified Axogen, Inc. (the “Company”) of his decision to resign as a member of the Company’s Board of Directors (the “Board”), including as a member of the Audit Committee and Compensation Committee, effective as of 11:59 PM EST on Wednesday, March 30, 2022.”

John Johnson was appointed as Director at Axogen, Inc..

“On July 16, 2021, the board of directors (the “Board”) of Axogen, Inc. (the “Company”) increased the size of the Board from eight to nine members, and appointed John Johnson as a new director, effective July 19, 2021.”